On June 8, 2026 Hengrui Pharma reported more than 90 studies spanning multiple tumor types and therapeutic modalities at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting was held in Chicago from May 29 to June 2 (local time). As one of the world’s leading oncology conferences, the ASCO (Free ASCO Whitepaper) Annual Meeting serves as a key venue for presenting advances in cancer research and clinical development..

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

According to statistics, 94 Chinese research projects were selected for oral presentations at ASCO (Free ASCO Whitepaper) this year, including 12 late-breaking abstracts, marking the third consecutive year of growth. At 2026 ASCO (Free ASCO Whitepaper) Annual Meeting, Hengrui Pharma presented 91 accepted studies and 11 oral presentations featuring innovative therapies, underscoring the breadth of the company’s oncology pipeline and ongoing investment in innovative drug development.

As a leading innovative pharmaceutical company in China, Hengrui continues to focus on oncology research and drug development. For 16 consecutive years, Hengrui has shared data from its oncology portfolio at the ASCO (Free ASCO Whitepaper) Annual Meeting. This year, the company’s research program encompasses multiple key areas, including gastrointestinal cancers, breast cancer, lung cancer, urological cancers, gynecological cancers, and supportive cancer care, covering 11 approved medicines, 10 pipeline candidates, and one Class 2 new drug (NMPA classification).

Breast Cancer: New Data Support Multiple Emerging Treatment Strategies

For triple-negative breast cancer, the HELEN-Trio 011 study led by Professor Zhenzhen Liu of Henan Cancer Hospital showed that the pathological complete response (pCR) rate for neoadjuvant therapy with camrelizumab combined with chemotherapy reached 57.5%, significantly outperforming the pCR of 45.4% observed with chemotherapy alone. In the field of neoadjuvant therapy for HER2-positive early breast cancer, the HELEN HER-013 study was the first to demonstrate that the chemotherapy-de-escalated regimen of nanoparticle albumin-bound paclitaxel, trastuzumab, and the tyrosine kinase inhibitor pyrotinib (nab-PHPy) is noninferior to standard TCHP, offering a new treatment option for patients who cannot tolerate severe hematologic toxicity.

Gastrointestinal Cancers: ADC and Immunotherapy Combination Treatments Show Promise

In the field of colorectal cancer, the HORIZON-CRC01 study led by Professor Jin Li of Shanghai GoBroad Cancer Hospital Affiliated to China Pharmaceutical University and Professor Ying Yuan of The Second Affiliated Hospital of Zhejiang University School of Medicine demonstrated that the new-generation anti-HER2 ADC, trastuzumab rezetecan, when used to treat patients with HER2-positive, RAS and RAF wild-type advanced colorectal cancer who have progressed after standard second-line therapy, achieved a median progression-free survival (PFS) of 5.5 months, compared to 2.8 months with standard-of-care (SOC), suggesting a potential new treatment option for patients whose disease has progressed following standard therapies. In the field of hepatocellular carcinoma, the phase III CARES-336 trial, led by Academician Jia Fan (Zhongshan Hospital, Fudan University) and Professor Shukui Qin (Tsientang Institute for Advanced Study)—demonstrated that the combination of camrelizumab plus rivoceranib with transarterial chemoembolization (TACE) significantly improved median progression-free survival (PFS) versus TACE alone (11.1 vs. 8.3 months; BICR-assessed per mRECIST).This triplet regimen represents a new benchmark for systemic-combined locoregional therapy for patients with unresectable HCC (uHCC).

Urological Cancers: Dual Breakthroughs in Prostate and Bladder Cancers

The FUZUPRO study, led by Professor Dingwei Ye of Fudan University Shanghai Cancer Center, demonstrated that first-line treatment with fluzoparib combined with abiraterone acetate and prednisone for metastatic castration-resistant prostate cancer (mCRPC) resulted in a median radiographic PFS of 24.8 months, compared to 19.9 months with the standard regimen. Another study demonstrated that the anti-Nectin-4 ADC SHR-A2102 combined with adebrelimab achieved a pCR of 48.1% and a pathological downstaging rate of 59.3% in the perioperative treatment of muscle-invasive bladder cancer, including those with renal dysfunction.

Supportive Cancer Care: Additional Evidence for New Antiemetic Drug

The Phase III PROTECT study, led by Professor Li Zhang and Professor Yuhong Li of the Sun Yat-sen University Cancer Center, demonstrated that Fosrolapitant and Palonosetron Hydrochloride for Injection—a novel, ultra-long-acting antiemetic developed in-house by Hengrui—achieved significantly higher complete response rates than the standard regimen during the acute, delayed, and overall phases for the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. These findings add to the growing body of clinical evidence supporting its use in supportive cancer care.

Hengrui Pharma currently markets 16 approved oncology medicines in China and is advancing nearly 60 oncology candidates across its research portfolio. The company is conducting more than 150 clinical trials worldwide across its key oncology development programs.

Hengrui’s expanding presence at the ASCO (Free ASCO Whitepaper) Annual Meeting reflects continued progress across its oncology pipeline and broader clinical development efforts. The company’s research presentations this year span multiple tumor types and therapeutic modalities, highlighting both approved medicines and investigational candidates across its oncology portfolio.

As oncology research continues to evolve globally, Hengrui remains focused on translating scientific innovation into potential clinical benefit for patients through sustained investment in research and development.

(Press release, Hengrui Pharmaceuticals, JUN 8, 2026, View Source [SID1234666491])

On June 8, 2026 Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting and multi-specific therapies, reported that preclinical data for KT209, its novel trispecific antibody candidate, will be presented in a poster session at the European Hematology Association (EHA) (Free EHA Whitepaper) (EHA 2026) Annual Congress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

KT209 is a novel trispecific antibody engineered to co-engage CD19, CD20, and CD3, redirecting endogenous T cells to achieve deep B-cell depletion. While traditional bispecific T-cell engagers (TCEs) targeting a single antigen face challenges with treatment failure due to antigen escape (low or lost CD19/CD20 expression), KT209’s dual-antigen targeting mechanism is designed to prevent escape and improve clinical outcomes. Enhanced by a proprietary CD3 masking design, KT209 delivers exceptional anti-tumor potency alongside a highly optimized safety profile.

Presentation Details

Poster Title: A NOVEL TRISPECIFIC ANTIBODY KT209 TARGETING CD19, CD20, AND CD3 (CD19XCD20XCD3) DEMONSTRATED POTENT ACTIVITY IN B-CELL DISEASES WITH LOWER CYTOKINE RELEASES
Poster Number: PF369
Session: Poster Session 1
Dates: Thursday, June 11 – Friday, June 12, 2026
Highly Differentiated Preclinical Profile

The upcoming poster presentation highlights comprehensive preclinical data evaluating KT209 across in vitro, in vivo, and non-human primate (NHP) models:

Resistance-Proof Cytotoxicity: KT209 demonstrated robust clearance against both Raji and Nalm19 leukemia cells. Crucially, in Nalm19 models—which express low levels of CD20—the approved TCE glofitamab suffered a significant drop-off in efficacy, whereas KT209 maintained potent tumor-killing activity.
Decoupling Potency from Toxicity: In head-to-head human PBMC assays, KT209 demonstrated a clear trend of lower inflammatory cytokine release compared to glofitamab, successfully mitigating the primary driver of Cytokine Release Syndrome (CRS).
In Vivo Tumor Clearance: In humanized NOG mouse models, KT209 achieved potent, dose-dependent anti-leukemia activity.
Favorable NHP Safety and Tolerability: In non-human primates, a single subcutaneous dose of KT209 triggered rapid and deep peripheral B-cell depletion at the lowest tested dose. The molecule was completely well-tolerated with zero clinical adverse events and only minimal, transient cytokine release restricted to the first dose.
Leadership Commentary

John Wang, Chief Scientific Officer of Kali Therapeutics, commented:

"The data to be showcased at EHA (Free EHA Whitepaper) underscores the highly differentiated profile of KT209. By integrating dual-antigen B-cell targeting with our proprietary CD3 masking technology, we have engineered a molecule that is fundamentally more potent than currently approved TCEs in low-antigen environments, yet operates with a much wider safety window. This allows us to achieve maximum tumor attrition while strictly limiting systemic cytokine release."

Weihao Xu, Chief Executive Officer of Kali Therapeutics, stated:

"Our presentation at EHA (Free EHA Whitepaper) 2026 marks a pivotal milestone in the strategic expansion of Kali. By bringing our platform into the oncology space, we are demonstrating that our ability to safely engage T-cells is truly drug-class agnostic. The unique safety profile of our TCEs, which has already validated our autoimmune pipeline, allows us to aggressively target hematologic malignancies where tumor escape and severe CRS have historically limited patient outcomes. With KT209, we look forward to advancing into first-in-human clinical trials in Q1 2027."

About KT209

KT209 is a novel CD19 x CD20 x CD3 trispecific antibody engineered using Kali’s proprietary multi-specific antibody platform. It is designed to maximize therapeutic efficacy by simultaneously binding to two distinct B-cell antigens (CD19 and CD20) and co-engaging CD3 on T cells. This dual-targeting approach minimizes the risk of tumor escape while its unique CD3 masking design controls T-cell activation kinetics, reducing cytokine release syndrome (CRS) risks while enabling complete removal of pathogenic B-cell populations.

(Press release, Kali Therapeutics, JUN 8, 2026, View Source [SID1234666490])

On June 8, 2026 TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage oncology company advancing a three-platform pipeline in RNA therapeutics and immuno-oncology, reported it will host its first live virtual R&D Webcast on Thursday, June 18, 2026, at 10:00 a.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast will provide strategic, scientific, and clinical program updates anchored by TransCode’s recently-initiated Phase 2a clinical trial of TTX-MC138 — the Company’s lead antagomiR program — in ctDNA-positive colorectal cancer, alongside portfolio and investment thesis updates across its development pipeline. A recording of the webcast will be made available on the Company’s website following the event.

Date:

Thursday, June 18, 2026

Time:

10:00 -11:15 a.m. Eastern Time

Format:

Live webcast, open access

Registration:

Will be made available on www.transcodetherapeutics.com as of June 11, 2026

Replay:

Webcast recording available on the Company’s website following the event

The webcast will cover:

TTX-MC138 Phase 2a clinical development, including trial design and strategic path forward
Pipeline and development strategy across the Company’s other candidates and platforms
Capital strategy, financial position, and long-term investment thesis
Featured speakers will include:

Guest: Keith Flaherty, MD — Director of Clinical Research, Massachusetts General Hospital Cancer Center; Professor of Medicine, Harvard Medical School; Member, TransCode Scientific Advisory Board
Philippe P Calais, PharmD, PhD — Chief Executive Officer and Chairman of the Board, TransCode Therapeutics
Dan Vlock, MD — Consulting Oncology Clinician, TransCode Therapeutics
Zdravka Medarova, PhD — Co-Founder and Chief Scientific Officer, TransCode Therapeutics
Louis Brenner, MD — Consulting Strategic Advisor, TransCode Therapeutics
Michel Janicot, PhD — Consulting Head of Translational Science, TransCode Therapeutics
"With TTX-MC138 now beginning enrollment in Phase 2a, and with two additional platform assets advancing on capital-disciplined timelines, TransCode is at a meaningful inflection point. This webcast is an opportunity to share for the first time in our Company’s history the scientific depth behind our programs, review the clinical data that supported our decision to move into the Phase 2a trial, and articulate the investment thesis underlying a three-platform pipeline. We look forward to engaging with our investors and the investment community."

(Press release, TransCode Therapeutics, JUN 8, 2026, View Source [SID1234666489])

On June 8, 2026 Curasight A/S ("Curasight" or "the Company") (Spotlight: CURAS) reported encouraging preliminary readout from its Phase 1 clinical trial with uTREAT in patients with aggressive brain cancer (glioblastoma).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A preliminary readout of the Phase 1 clinical trial with uTREAT in glioblastoma, an aggressive brain cancer, has now been undertaken. The data support:

The feasibility and safety of the mode of administration, super-selective intra-arterial cerebral injection (super-SIACI) with local, transient opening of the blood-brain barrier (BBB) using mannitol
High uptake and retention in tumor
Biodistribution and dosimetry compatible with the ability to deliver a therapeutically relevant radiation dose to the tumor without reaching dose limits for healthy organs
The data support continued development of Curasight’s therapeutic program using uTREAT in aggressive brain cancer
"The preliminary readout of our Phase 1 clinical trial with uTREAT in glioblastoma is encouraging and supports the ability of our technology to safely deliver therapeutically relevant radiation doses to the tumor without reaching dose limits for healthy organs. With these data, we are confident in moving forward with the Phase 1 trial and the development program for uTREAT, with the ambition of developing a potentially game-changing radioligand therapy for patients with glioblastoma," said Curasight’s CEO Ulrich Krasilnikoff.

About the Phase 1 trial with uTREAT in brain cancer

The trial aims to investigate Curasight’s uTREAT as a new targeted radioligand therapy for patients with glioblastoma. Participants in the trial are patients with newly diagnosed, verified or suspected GBM. uTREAT is administered via a catheter directly into the vessels that feed the tumor (super SIACI). To enhance tumor targeting, the blood-brain barrier is transiently opened with the osmotic compound mannitol. The mode of administration is designed to achieve high binding of uTREAT in tumors while minimizing radiation exposure to healthy organs.

(Press release, Curasight, JUN 8, 2026, View Source [SID1234666488])

On June 8, 2026 AbbVie (NYSE: ABBV) reported it will share new data at the European Hematology Association (EHA) (Free EHA Whitepaper) 2026 Congress and will showcase clinical advancements from research programs across multiple blood cancers, including multiple myeloma (MM), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and amyloidosis (AL). Featured data from AbbVie’s blood cancer portfolio and pipeline include 21 oral and poster presentations, highlighting the investigational compound etentamig (ABBV-383), and approved therapies, EPKINLY (epcoritamab-bysp) (TEPKINLY in the EU), VENCLEXTA (venetoclax) (VENCLYXTO in the EU) and DECNUPAZ (pivekimab sunirine-pvzy).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The compelling data we are presenting at EHA (Free EHA Whitepaper) reflect AbbVie’s robust portfolio and pipeline and our ongoing work to advance the treatment and understanding of hematologic cancers," said Daejin Abidoye, M.D., vice president, therapeutic area head, oncology, solid tumor and hematology, AbbVie. "With this research, we continue our commitment to pioneering innovative solutions that have the potential to elevate standards of care for patients and help address the most pressing challenges in treating blood cancers."

Key oral presentations of epcoritamab data include:

Treatment impact of epcoritamab with lenalidomide and rituximab in relapsed or refractory (R/R) FL
A subgroup analysis of the Phase 3 EPCORE FL-1 trial (NCT05409066) of fixed-duration epcoritamab, in combination with rituximab plus lenalidomide (E+R2) for patients with R/R FL (n=243), was performed to determine if the efficacy benefit and tolerability of E+R2 extended across clinically relevant subgroups, including patients with higher- and lower-risk disease features, compared to R2.1
Between Follicular Lymphoma International Prognostic Index (FLIPI) subgroups, overall response rate (ORR) was numerically higher with E+R2 compared to R2 (FLIPI 0–2, 96.5% vs 84.8%; FLIPI 3–5, 93.0% vs 72.6%).1 A similar trend was seen in those with progression of disease less than or equal to two years from the date of initial frontline therapy (POD24).1
Across the age subgroups, ORR and complete response rates (CRR) for E+R2 and R2 for ≥65 were (94.3% vs 80.2% and 80.7% vs 44.3%, respectively) and <65 (95.5% vs 78.4% and 83.9% vs 54.0%, respectively). Progression-free survival (PFS) hazard ratios (HRs) (95% CIs) for E+R2 and R2 for the NHL-5 low co-morbidity index score were (0.27 [0.17–0.42]) and NHL-5 high + intermediate were (0.14 [0.06–0.29]).1
The E+R2 safety profile across all subgroups was consistent with the overall trial population, with no new safety signals.1
Efficacy data of epcoritamab following systemic therapy in R/R large B-cell lymphoma (LBCL)
EPCORE DLBCL-1 (EudraCT No. 2020-003016-27) is a randomized Phase 3 trial in R/R LBCL evaluating epcoritamab, a CD3×CD20 bispecific antibody, monotherapy. The study showed a statistically significant improvement in PFS versus investigator’s choice of chemoimmunotherapy (CIT) — either rituximab plus gemcitabine plus oxaliplatin or bendamustine plus rituximab (HR 0.74 [95% CI, 0.60–0.92]; P=0.0059; 24-month PFS: 30% vs 13%). The study did not demonstrate a statistically significant improvement in overall survival (OS) (HR: 0.96 [95% CI, 0.77–1.20]). There was no OS detriment per pre-specified criteria.*2
Epcoritamab reported a CRR of 38% and CIT 26%; (nominal P value 0.0032), duration of response (DOR) (median DOR 37 vs 6 months; duration of complete response (DOCR) NR vs 11 months, respectively) and time to next treatment (TTNT) (7 vs 4 months, respectively; nominal P value <0.0001).2
Higher rates of grade 3–4 infections (30% vs 12%) and any-grade COVID-19 (36% vs 11%) were reported in the epcoritamab arm. Grade 5 treatment-emergent adverse events (TEAEs) occurred in 17% vs 6% (exposure-adjusted, 1.5 vs 1.8 per 100 pt-mo) and were largely attributable to grade 5 COVID-19 (9% vs 2%).2
*OUS the protocol and SAP were amended to include dual primary endpoints of OS and PFS

The following studies featuring venetoclax, etentamig and pivekimab sunirine-pvzy data will also be shared as oral and poster presentations:

Predicted efficacy of venetoclax-based therapies in CLL based on genetic biomarkers
Results from the Phase 3 GAIA/CLL13 (NCT02950051) trial evaluating fixed-duration venetoclax-based combinations (with rituximab, obinutuzumab and obinutuzumab plus ibrutinib) as a chemotherapy-free alternative to chemoimmunotherapy (fludarabine, cyclophosphamide and rituximab or bendamustine and rituximab) in fit, previously untreated CLL patients lacking del(17p) or TP53 mutations.3
Venetoclax in combination with rituximab and obinutuzumab plus ibrutinib in previously untreated CLL patients lacking del(17p) or TP53 mutations are investigational combinations not approved in the EU.
Efficacy and safety data of venetoclax-obinutuzumab combination in previously untreated CLL
Results from the open-label Phase 3 CLL14 trial (NCT02242942) comparing the efficacy and safety of venetoclax in combination with obinutuzumab to obinutuzumab plus chlorambucil in previously untreated patients with CLL and coexisting medical conditions.4
Real-world management practices with venetoclax-based therapy for AML
Results from the prospective observational study, REVIVE (NCT03987958), examining the effect of antimicrobial prophylaxis, post-remission administration of G-CSF and treatment initiation setting on safety and effectiveness outcomes with venetoclax plus hypomethylating agents (HMA) in newly diagnosed AML patients unfit for intensive chemotherapy.5
Etentamig in patients with relapsed/refractory multiple myeloma (RRMM) with prior exposure to B-cell maturation antigen (BCMA)-targeted therapy
Results from Arm B of the MONVISO study (NCT05650632), evaluating a flat dose of etentamig in patients with RRMM with at least two prior lines of therapy, including triple-class and prior BCMA exposure. The Phase 1b study is assessing dose optimization and safety.6
Etentamig is an investigational therapy not approved in the EU.
Longer term safety and efficacy data of etentamig monotherapy in R/R light chain amyloidosis
Updated results from M24-209 (NCT06158854), evaluating etentamig monotherapy in BCMA-targeted therapy-naïve patients with relapsed/refractory immunoglobulin light chain amyloidosis. The open-label Phase 1/2 study is assessing dose escalation safety and efficacy.7
Etentamig is an investigational therapy not approved in the EU.
Efficacy data of pivekimab sunirine-pvzy in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) with baseline skin involvement in the CADENZA study
Post-hoc analysis from CADENZA (NCT03386513), evaluating the first-line use of pivekimab sunirine-pvzy in patients with BPDCN and varying degrees of skin involvement. The open-label Phase 1/2 study is assessing overall response rate, overall survival and percentage of eligible patients approved to proceed with a stem cell transplant.8
Pivekimab sunirine-pvzy is an investigational therapy not approved in the EU.
Details on key oral and poster presentations at the EHA (Free EHA Whitepaper) 2026 Congress are available below and the full abstracts are available here.

Oral Presentations:

Title

Date/Time

Session

Abstract/ Presentation Number

Clinically Relevant Subgroup Analysis from the Randomized Phase 3 EPCORE FL-1 Trial: Treatment (Tx) Effect of Epcoritamab with Lenalidomide and Rituximab (R2) in R/R Follicular Lymphoma (FL)

Thursday, June 11,

17:45 – 18:00 CEST

Oral Session,

K1 Hall

EHA-3041

Short: S229

Results from EPCORE DLBCL-1: Randomized Phase 3 Study of Epcoritamab (Epcor) Vs Investigator’s Choice Chemoimmunotherapy (CIT) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL)

Friday, June 12,
17:15 – 17:30 CEST

Oral Session,

Nobel Hall

EHA-2409

Short: S235

Venetoclax-obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: Final Results of the Randomized CLL14 Study

Friday, June 12,

17:30 – 17:45 CEST

Oral Session,

AE1 Hall

EHA-2488

Short: S146

Genetic Biomarkers Predicting Sustained Efficacy of Venetoclax-based Therapies or CIT in Chronic Lymphocytic Leukemia: Final 5-year Analysis of the GAIA/CLL13 Trial

Friday, June 12,
18:15 – 18:30 CEST

Oral Session,

AE1 Hall

EHA-4841

Short: S149

Phase 1 Dose Escalation Safety and Efficacy of Etentamig in Patients with Relapsed or Refractory Light Chain Amyloidosis

Friday, June 12,
18:15 – 18:30 CEST

Oral Session,

Victoria Hall

EHA-1134

Short: S209

Fixed Duration Venetoclax Plus Epcoritamab Shows Favorable Tolerability and High Response Rates with Early Molecular Responses in R/R CLL/SLL: Interim Analysis of the Randomized HOVON 165/AETHER Trial

Sunday, June 14,
11:45 – 12:00 CEST

Oral Session,

A10-11 Hall

EHA-3784

Short: S153

Poster Presentations:

Sustained Remissions Beyond 4 Years with Epcoritamab Monotherapy: Long-term Follow-up Results from the Pivotal EPCORE NHL-1 Trial in Patients with Relapsed or Refractory Large B-cell Lymphoma

Friday, June 12,
18:45 CEST

Poster Session, Hall A

EHA-2191

Short: PF977

Epcoritamab + R-mini-chop Results In 2-year Remissions and High MRD-negativity Rates in Elderly Patients with Newly Diagnosed DLBCL: Results from the EPCORE NHL-2 Trial

Friday, June 12,
18:45 CEST

Poster Session,

Hall A

EHA-2359

Short: PF1007

Reduced CD20 Expression and Intratumoral CD3+ T Cells Following Epcoritamab Treatment Are Associated with Progressive Disease in a Subset of Diffuse Large B-cell Lymphoma and Follicular Lymphoma

Friday, June 12,
18:45 CEST

Poster Session, Hall A

EHA-2343

Short: PF1069

Pharmacodynamic Biomarkers Support the Clinical Benefit of Epcoritamab Plus Rituximab and Lenalidomide (R2) In Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL): Analyses from EPCORE FL-1

Friday, June 12,
18:45 CEST

Poster Session, Hall A

EHA-3123

Short: PF1081

Real-world Management Practices with Venetoclax-based Therapy For AML – Results from the Prospective REVIVE Study

Friday, June 12,
18:45 CEST

Poster Session,

Hall A

EHA-3291

Short: PF536

The Efficacy of Pivekimab Sunirine (PVEK) in Patients (PTS) with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) with Baseline Skin Involvement in the CADENZA Study

Friday, June 12,
18:45 CEST

Poster Session,

Hall A

EHA-1950

Short: PF500

Anchored Matching-adjusted Indirect Comparison of Epcoritamab, Lenalidomide, and Rituximab Vs Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular Lymphoma: EPCORE FL-1 Vs Inmind

Saturday, June 13,
18:45 CEST

Poster Session, Hall A

EHA-1124

Short: PS2035

Comparative Effectiveness of Epcoritamab, Lenalidomide, and Rituximab in EPCORE FL-1 Vs Real-world Chemoimmunotherapy in Relapsed/Refractory Follicular Lymphoma

Saturday, June 13,
18:45 CEST

Poster Session, Hall A

EHA-3065

Short: PS2042

Comparative Analyses of Epcoritamab in Combination with Lenalidomide and Rituximab Vs Obinutuzumab and Bendamustine in Relapsed/Refractory Follicular Lymphoma

Saturday, June 13,
18:45 CEST

Poster Session, Hall A

EHA-3140

Short: PS2052

Epcoritamab + Chemoimmunotherapy in Patients with Relapsed/Refractory Large B-cell Lymphoma Eligible for Autologous Stem Cell Transplant: Pooled Results from Arms 4 and 10 of EPCORE NHL-2

Saturday, June 13,
18:45 CEST

Poster Session,

Hall A

EHA-2303

Short: PS2070

Fixed-duration Epcoritamab Monotherapy Induces High Response and MRD-negativity Rates in Elderly Patients with Newly Diagnosed Large B-cell Lymphoma and Comorbidities: Results from EPCORE DLBCL-3

Saturday, June 13,
18:45 CEST

Poster Session, Hall A

EHA-2346

Short: PS2082

Epcoritamab In Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL): Insights from the Real-world Epcoritamab Patient Characteristics and Outcomes Research (Real-epcor) Study

Saturday, June 13,
18:45 CEST

Poster Session, Hall A

EHA-2202

Short: PS2086

Epcoritamab Plus Lenalidomide and Rituximab Improves or Preserves Health-related Quality of Life in Patients with Relapsed/Refractory Follicular Lymphoma Who Had High Symptom Burden or Adverse Events

Saturday, June 13,
18:45 CEST

Poster Session, Hall A

EHA-2776

Short: PS2497

Quality of Life and Symptoms with Fixed-duration Acalabrutinib + Venetoclax ± Obinutuzumab Vs Chemoimmunotherapy in Treatment-naive Chronic Lymphocytic Leukemia: Patient-Reported Outcomes from AMPLIFY

Saturday, June 13,
18:45 CEST

Poster Session,

Hall A

EHA-4662

Short: PS1706

Etentamig In Patients (PTS) with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to B-cell Maturation Antigen (BCMA)-targeted Therapy

Saturday, June 13,
18:45 CEST

Poster Session,

Hall A

EHA-2799

Short: PS1913

Etentamig (ABBV-383) is an investigational medicine and is not approved by any health authorities worldwide. The safety and efficacy of this medicine is under evaluation as part of ongoing clinical studies. Pivekimab sunirine is not approved in the EU.

EPKINLY/TEPKINLY (epcoritamab) and VENCLEXTA/VENCLYXTO (venetoclax) are approved medicines being investigated for additional uses. Safety and efficacy have not been established for these unapproved additional uses.

EPKINLY/TEPKINLY (epcoritamab) is being co-developed by Genmab and AbbVie as part of the companies’ oncology collaboration. The companies share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization.

VENCLEXTA/VENCLYXTO (venetoclax) is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.

Additional information on AbbVie clinical trials is available at View Source

USE & IMPORTANT SAFETY INFORMATION for EPKINLY (epcoritamab-bysp) in U.S.

What is EPKINLY?
EPKINLY is a prescription medicine used to treat adults with:

certain types of diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma that has come back (relapsed) or that did not respond (refractory) after 2 or more treatments.
follicular lymphoma (FL) that has come back or that did not respond to previous treatment, together with lenalidomide and rituximab
follicular lymphoma (FL) that has come back or that did not respond after 2 or more treatments.
EPKINLY for the treatment of DLBCL is approved based on patient response data. Studies are ongoing to confirm the clinical benefit of EPKINLY.

It is not known if EPKINLY is safe and effective in children.

IMPORTANT SAFETY INFORMATION
Important Warnings—EPKINLY can cause serious side effects, including:

Cytokine release syndrome (CRS), which is common during treatment with EPKINLY and can be serious or lead to death. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 or 3 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule.
Neurologic problems that can be serious, and can be life-threatening, and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY.
People with DLBCL or high-grade B-cell lymphoma may be hospitalized after receiving their first full dose of EPKINLY on Day 15 of Cycle 1 due to the risk of CRS and neurologic problems.

People with FL may be hospitalized after receiving their first full dose of EPKINLY on Day 22 of Cycle 1 due to the risk of CRS and neurologic problems.

Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. These may be symptoms of CRS or neurologic problems. If you have any symptoms that impair consciousness, do not drive or use heavy machinery or do other dangerous activities until your symptoms go away.

EPKINLY can cause other serious side effects, including:

Infections that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, feeling weak or generally unwell, or confusion.
Low blood cell counts, which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia and lymphopenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems.
Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. If you are a female who can become pregnant, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.

The most common side effects of EPKINLY when used alone in DLBCL or high-grade B-cell lymphoma or FL include CRS, injection site reactions, tiredness, muscle and bone pain, fever, diarrhea, COVID-19, rash, and stomach-area (abdominal) pain. The most common severe abnormal laboratory test results with EPKINLY when used alone include decreased white blood cells, decreased red blood cells, and decreased platelets.

The most common side effects of EPKINLY when used together with lenalidomide and rituximab in FL include rash, upper respiratory tract infections, tiredness, injection site reactions, constipation, diarrhea, CRS, pneumonia, COVID-19, and fever. The most common severe abnormal laboratory test results with EPKINLY when used together with lenalidomide and rituximab include decreased white blood cells and decreased platelets.

These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects.

You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622).

Please see Full Prescribing Information and Medication Guide, including Important Warnings.

Globally, prescribing information varies. Refer to the individual country product label for complete information.

USE & IMPORTANT SAFETY INFORMATION for VENCLEXTA (venetoclax tablets) in U.S.

Uses

VENCLEXTA is a prescription medicine used:

to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
in combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with newly diagnosed acute myeloid leukemia (AML) who:
‒ are 75 years of age or older, or
‒ have other medical conditions that prevent the use of standard chemotherapy.
It is not known if VENCLEXTA is safe and effective in children.

Important Safety Information

What is the most important information I should know about VENCLEXTA?

VENCLEXTA can cause serious side effects, including:
Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure, the need for dialysis treatment, and may lead to death. Your healthcare provider will do tests to check your risk of getting TLS before you start taking VENCLEXTA. You will receive other medicines before starting and during treatment with VENCLEXTA to help reduce your risk of TLS. You may also need to receive intravenous (IV) fluids into your vein. Your healthcare provider will do blood tests to check for TLS when you first start and during treatment with VENCLEXTA. It is important to keep your appointments for blood tests. Tell your healthcare provider right away if you get any symptoms of TLS during treatment with VENCLEXTA, including fever, chills, nausea, vomiting, confusion, shortness of breath, seizures, irregular heartbeat, dark or cloudy urine, unusual tiredness, or muscle or joint pain.

Drink plenty of water during treatment with VENCLEXTA to help reduce your risk of getting TLS. Drink 6 to 8 glasses (about 56 ounces total) of water each day, starting 2 days before your first dose, on the day of your first dose of VENCLEXTA, and each time your dose is increased.

Your healthcare provider may delay, decrease your dose, or stop treatment with VENCLEXTA if you get symptoms of TLS. When restarting VENCLEXTA after stopping for 1 week or longer, your healthcare provider may check again for your risk of TLS and change your dose.

Who should not take VENCLEXTA?

Patients taking certain medicines during the beginning of VENCLEXTA (when the dose is being slowly increased) are at increased risk of TLS.

Tell your healthcare provider about all the medicines you take, including prescription and over-the- counter medicines, vitamins, and herbal supplements. VENCLEXTA and other medicines may affect each other causing serious side effects.
Do not start new medicines during treatment with VENCLEXTA without first talking with your healthcare provider.
Before taking VENCLEXTA, tell your healthcare provider about all of your medical conditions, including if you:

have kidney or liver problems.
have problems with your body salts or electrolytes, such as potassium, phosphorus, or calcium.
have a history of high uric acid levels in your blood or gout.
are scheduled to receive a vaccine. You should not receive a "live vaccine" before, during, or after treatment with VENCLEXTA, until your healthcare provider tells you it is okay. If you are not sure about the type of immunization or vaccine, ask your healthcare provider. These vaccines may not be safe or may not work as well during treatment with VENCLEXTA.
are pregnant or plan to become pregnant. VENCLEXTA may harm your unborn baby.
Females who are able to become pregnant:
‒ Your healthcare provider should do a pregnancy test before you start treatment with VENCLEXTA.
‒ Use effective birth control during treatment and for 30 days after the last dose of VENCLEXTA.
‒ If you become pregnant or think you are pregnant, tell your healthcare provider right away.
are breastfeeding or plan to breastfeed. It is not known if VENCLEXTA passes into your breast milk. Do not breastfeed during treatment with VENCLEXTA and for 1 week after the last dose.
What should I avoid while taking VENCLEXTA?
You should not drink grapefruit juice or eat grapefruit, Seville oranges (often used in marmalades), or starfruit during treatment with VENCLEXTA. These products may increase the amount of VENCLEXTA in your blood.

What are the possible side effects of VENCLEXTA?

VENCLEXTA can cause serious side effects, including:

Low white blood cell counts (neutropenia). Your healthcare provider will do blood tests to check your blood count during treatment with VENCLEXTA and may pause dosing of VENCLEXTA or give you medicines to help treat your neutropenia if it is severe.
Infections. Death and serious infections such as pneumonia and blood infection (sepsis) have happened during treatment with VENCLEXTA. Your healthcare provider will closely monitor and treat you right away if you get a fever or any signs of infection during treatment with VENCLEXTA.
Tell your healthcare provider right away if you get a fever or any signs of an infection during treatment with VENCLEXTA.

The most common side effects of VENCLEXTA when used in combination with acalabrutinib in people with CLL or SLL include low white blood cell count, headache, diarrhea, muscle and bone pain, and COVID-19.

The most common side effects of VENCLEXTA when used in combination with obinutuzumab or rituximab or alone in people with CLL or SLL include low white blood cell count; low platelet count; low red blood cell count; diarrhea; nausea; upper respiratory tract infection; cough; muscle and joint pain; tiredness; and swelling of your arms, legs, hands, and feet.

The most common side effects of VENCLEXTA in combination with azacitidine or decitabine or low-dose cytarabine in people with AML include nausea; diarrhea; low platelet count; constipation; low white blood cell count; fever with low white blood cell count; tiredness; vomiting; swelling of arms, legs, hands, or feet; fever; infection in lungs; shortness of breath; bleeding; low red blood cell count; rash; stomach (abdominal) pain; infection in your blood; muscle and joint pain; dizziness; cough; sore throat; and low blood pressure.

Your healthcare provider may temporarily stop VENCLEXTA treatment, decrease your dose, or completely stop treatment if you get severe side effects.

VENCLEXTA may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of VENCLEXTA. Call your doctor for medical advice about side effects.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you cannot afford your medication, contact genentech-access.com/patient/brands/venclexta for assistance.

Please see full Prescribing Information. Globally, prescribing information varies. Refer to the individual country product label for complete information.

U.S. Prescribing Information for AbbVie Medicines

Please see full Prescribing Information including BOXED WARNING for DECNUPAZ (pivekimab sunirine-pvzy)

(Press release, AbbVie, JUN 8, 2026, View Source [SID1234666487])